Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Recursion Pharmaceuticals Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.6, while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). Which is the better fit depends on your goals.
| NVDY | RXRX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.96 | $6.79 |
52-Week Low | $12.03 | $2.84 |
Market Cap | — | $1.53B |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.41, showing modest daily gains of 0.4%. The ETF employs a covered call strategy on NVIDIA shares, generating weekly distributions but capping upside potential. Technical indicators signal bearish momentum with moving averages and ADX pointing downward, while oscillators remain neutral. Recent distributions have ranged from $0.10 to $0.21 per share, providing income-focused investors with regular cash flow.
The outlook remains challenging as the covered call strategy sacrifices NVIDIA's explosive growth potential for income generation. Key risks include opportunity cost from missed upside, fund management fees, and dependence on NVIDIA's volatility. While attractive for income seekers, growth-oriented investors may prefer direct NVIDIA exposure given the significant performance trade-off.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
